Sort
10,766 grants matching “checkpoint inhibitor”
Elucidating mechanisms underlying replication checkpoint control
$499,417Junjie Chen · University Of Tx Md Anderson Can Ctr · R01 · FY2023 · CA
Elucidating mechanisms underlying replication checkpoint control
$499,417Junjie Chen · University Of Tx Md Anderson Can Ctr · R01 · FY2025 · CA
Tackling Treg mediated resistance to radiation and anti-PDL1 in HNSCC's
$499,311Sana D Karam · Washington University · R01 · FY2025 · DE
Inhibition of wild-type IDH1 as a ferroptosis-inducing therapeutic approach for the treatment of malignant glioma.
$499,261Alexander H. Stegh · Washington University · R01 · FY2023 · NS
Targeting lymph node metastases to block cancer progression
$499,258Timothy P Padera · Massachusetts General Hospital · R01 · FY2023 · CA
Targeting lymph node metastases to block cancer progression
$499,258Timothy P Padera · Massachusetts General Hospital · R01 · FY2025 · CA
Mechanisms of PD-1 and Tim-3 crosstalk in tumor-infiltrating lymphocytes
$499,177Robert L Ferris · University Of Pittsburgh At Pittsburgh · R01 · FY2018 · CA
Role of AMPK in melanoma brain metastasis
$499,166Bin Zheng · Massachusetts General Hospital · R01 · FY2023 · CA
Dual-specificity phosphatase action in muscle disease
$499,077Anton M Bennett · Yale University · R01 · FY2024 · AR
Dual-specificity phosphatase action in muscle disease
$499,077Anton M Bennett · Yale University · R01 · FY2025 · AR
Project 3 Immunotherapeutic Targeting of SLC45A2 for Treatment of Uveal Melanoma
$498,957Cassian Yee · University Of Tx Md Anderson Can Ctr · P50 · FY2020 · CA
Enhancing the Potency and Durability of Immunotherapies
$498,946Robert C Seeger · Children'S Hospital Of Los Angeles · P01 · FY2019 · CA
Checkpoint Function of PTPalpha in Pathological Fibrogenesis in the Lung
$498,875Gregory Paul Downey · National Jewish Health · R01 · FY2017 · HL
Inhibition of wild-type IDH1 as a ferroptosis-inducing therapeutic approach for the treatment of malignant glioma.
$498,788Alexander H. Stegh · Washington University · R01 · FY2022 · NS
New Pathways in Thrombosis and Inflammation Mediated by Semaphorin-Plexin Signali
$498,737Guy A. Zimmerman · University Of Utah · RC1 · FY2009 · HL
Defining a globally accessible and pragmatic predictive signature (GAPPS) for locally advanced cervical cancer
$498,565Ann Klopp · University Of Tx Md Anderson Can Ctr · R01 · FY2025 · CA
Targeting the innate immune response in HNSCC
$498,386Judith A. Varner · University Of California, San Diego · R01 · FY2023 · DE
Targeting the innate immune response in HNSCC
$498,386Judith A. Varner · University Of California, San Diego · R01 · FY2022 · DE
Targeting the innate immune response in HNSCC
$498,386Judith A. Varner · University Of California, San Diego · R01 · FY2025 · DE
Targeting tumor and T cell DNA methylomes to improve CAR T cell therapies for diffuse midline glioma
$498,337Stephen C Mack · St. Jude Children'S Research Hospital · U01 · FY2025 · CA
Defining and targeting epigenetic plasticity-driven drug resistance and immune escape in melanoma
$498,307Keiran Smalley · H. Lee Moffitt Cancer Ctr & Res Inst · R01 · FY2022 · CA
New Pathways in Thrombosis and Inflammation Mediated by Semaphorin-Plexin Signali
$498,264Guy A. Zimmerman · University Of Utah · RC1 · FY2010 · HL
Cyclin Dependent Kinases as Epigenetic Therapy Targets
$498,235Jean-Pierre J Issa · Coriell Institute For Medical Research · P50 · FY2023 · CA
Cyclin Dependent Kinases as Epigenetic Therapy Targets
$498,233Jean-Pierre J Issa · Coriell Institute For Medical Research · P50 · FY2022 · CA
Protein Kinase Signaling and Cell Cycle Control
$498,230Michael B Yaffe · Massachusetts Institute Of Technology · R01 · FY2014 · ES